Amgen Faces Lawsuit For Hiding Its Stupendous Tax Bill Of $10B
In a complaint filed in Manhattan federal court, a Detroit-based pension fund said Amgen Inc (NASDAQ:AMGN) concealed the dispute over…
Analyst Says Biogen-Eisai’s Alzheimer’s Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Eisai Co Ltd (OTC:ESALY) and Biogen Inc (NASDAQ:BIIB) said the U.S. Department of Veteran Affairs (VA) would provide coverage of their…
Synaffix Has Announced The Expansion Of Its License Agreement With Macrogenics Adding Up To Four Antibody-drug Conjugates Programs; Expanded Collaboration Includes Up To $2.2B In Total Potential Payments
The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion, plus tiered low to high single-digit royalties on potential net
Atea Pharmaceuticals Announced The Presentation Of New Phase 1, In Vitro And In Vivo Data That Demonstrate Key Profile Attributes Of Atea’s Lead Drug Candidate, Bemnifosbuvir, For Covid-19 And Hepatitis C
Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies
Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern evaluated as well as
Enanta Pharmaceuticals To Present New Data For EDP-235 In Development As An Oral, Once-daily Treatment For Covid-19, At The International Conference On Antiviral Research
Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir
Preclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household
Philips And The Gibraltar Health Authority Have Signed A Long-term Strategic Partnership Continuing Their Long-standing Relationship And Marking Ambitions To Advance Radiology And Cardiology Patient Care
As part of the agreement, the building of a brand-new interventional cardiac suite (cath lab) will commence later this year. The construction and installation of this specialist equipment will take approximately 9-12As part of the agreement, the building of a brand-new interventional cardiac suite (cath lab) will commence later this year.
OKYO Pharma Announces $5.74M Private Placement And Investment By Directors, Senior Management Members
OKYO will issue 3,503,665 new ADSs (representing 227,738,225 new Ordinary Shares) ("New ADSs") to certain investors at a price of U.S.$1.50 per New ADS ("U.S. Offering Price") raising gross
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts were immaterial to their operations.
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Bristol Myers Squibb & Co’s (NYSE:BMY) Eliquis, Pfizer Inc’s (NYSE:PFE) Ibrance, and AbbVie Inc’s (NYSE:ABBV) Imbruvica are expected to be among the ten…
Provention Bio’s $2.9B Acquisition – A Strategic Fit For Sanofi
Sanofi SA (NASDAQ:SNY) has agreed to acquire Provention Bio Inc (NASDAQ:PRVB) for $25.00 per share in cash, representing an equity value of approximately…